Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
about
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.The prospects of pazopanib in advanced renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsetsHuman renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.Cytokine therapy reverses NK cell anergy in MHC-deficient tumorsCritical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinomaProstaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patientsIdentification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor EffectComparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsImmunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis.Anti-angiogenic therapy in renal cell cancer.Thigh mass in a 73-year-old manEstablishing the role of cytokine therapy in advanced renal cell carcinoma.Cytokines in cancer immunotherapy.Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overviewTumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.Sarcoma immunotherapy: past approaches and future directions.First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis.Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells.Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib.Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
P2860
Q30423599-5086D2C9-D19D-4FA5-8BF8-EC7E79BF79AAQ33479314-FE08CEB1-8CD2-4B73-ACF0-1DDF0AA8A86DQ33716744-6E924072-FD07-4EC5-916B-D608D80F19C0Q34656393-6E053C23-0BC2-44ED-8032-4C64FCB534BDQ34661185-25D8F9B6-2649-425B-8E99-5E99BB0200A6Q35012607-FA34FA58-D22B-45CB-8371-1F362C998B07Q35070193-4E0978ED-21DC-406C-B631-1BC6DDE3AD11Q35140125-9CF40678-DC02-44E5-9892-51C21CA005F5Q35212949-42AA0EBC-8991-4B03-9E18-EE1242BF9F25Q35311177-4042775C-E76C-4800-9DDB-384848E101A6Q35753007-B6581035-AE97-4313-98DB-3D110B378E13Q36162804-6F631AB8-215E-4E6E-A877-1F7A573B0112Q36436914-536ED994-0A8A-41D2-ABC3-F3FAB0DE4805Q36500548-623ED680-3852-4AFD-A364-C8782F1E1486Q36611853-299EA771-8542-4916-A660-79F67F470ACEQ36680692-DC35637E-C894-4E32-9BBB-8867764C7F0AQ36794815-7271A25A-8763-411B-BB9E-1DC95A343D90Q37072548-9B8C3FCF-0F01-4DF9-82A2-A7A1D6B7A12BQ37086157-47F9E14F-5E08-4471-9C3A-A40631A5CCE8Q37148152-C612BA1F-49CD-480B-8816-9E97AA1F9CA3Q37153399-8DFCDAEF-9738-42B0-99B3-E2D21FA5CA2CQ37403755-D53E2F3E-B6E9-4FFD-836D-5C18B4B12C14Q37422116-ABC92D02-1D76-436B-A15F-9AFC6606630FQ37575635-910D7E67-FCAB-45E2-BB11-FB21181DFE77Q37952233-3809A418-341E-45FF-9D7E-1978BF02E9DFQ38068922-E59E7E49-E69A-4C56-A203-CC2C882F5C3FQ38207986-12CE4925-5276-4DBD-9D2D-9575415DBA14Q38550942-89CC4870-6BA3-4AFB-9F2A-AF7289380233Q38772887-519CEA17-7C63-4D22-AD26-71F263DB8F5AQ39275844-10131C94-6A6A-4B77-ADED-D0E5319C73FAQ41456207-6FD2990A-BE62-4F77-B9D3-6F9CF0B38E82Q41948917-AA2975E7-76E2-46E8-A59E-3F5310BEDF70Q46465112-ED4F521B-6B85-47E3-A3CB-D3309C81A0BDQ46963498-97E13A3D-9056-45AB-AF61-2D66E4E129BBQ47358265-5FDE9391-6457-4C02-8838-9A49190CF0A8Q49919933-D5F95F20-230A-40CA-A1F0-E0EC038D071A
P2860
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Update on the role of interleu ...... with stage IV renal carcinoma.
@ast
Update on the role of interleu ...... with stage IV renal carcinoma.
@en
type
label
Update on the role of interleu ...... with stage IV renal carcinoma.
@ast
Update on the role of interleu ...... with stage IV renal carcinoma.
@en
prefLabel
Update on the role of interleu ...... with stage IV renal carcinoma.
@ast
Update on the role of interleu ...... with stage IV renal carcinoma.
@en
P2093
P1476
Update on the role of interleu ...... with stage IV renal carcinoma.
@en
P2093
David McDermott
Meredith Regan
Michael B Atkins
P304
P356
10.1158/1078-0432.CCR-040029
P407
P433
P577
2004-09-01T00:00:00Z